HighTower Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

HighTower Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16,650	Closed	-$20K	–	3468
2022 Q2	$20K	Buy	+16,650	New	+$21.2K	﹤0.01%	2998
2020 Q4	–	Sell	-35,293	Closed	-$117K	–	2996
2020 Q3	$117K	Sell	35,293 -6,300	-15%	-$23.1K	﹤0.01%	2209
2020 Q2	$141K	Hold	41,593	–	–	﹤0.01%	2066
2020 Q1	$159K	Sell	41,593 -2,250	-5%	-$10.5K	﹤0.01%	1848
2019 Q4	$265K	Sell	43,843 -25	-0.1%	-$171	﹤0.01%	1796
2019 Q3	$333K	Sell	43,868 -20,125	-31%	-$227K	﹤0.01%	1723
2019 Q2	$867K	Sell	63,993 -31,500	-33%	-$364K	0.01%	1253
2019 Q1	$518K	Buy	95,493 +11,000	+13%	+$53.5K	﹤0.01%	1446
2018 Q4	$251K	Sell	84,493 -7,250	-8%	-$39.7K	﹤0.01%	1705
2018 Q3	$748K	Buy	91,743 +8,350	+10%	+$64.1K	0.01%	1263
2018 Q2	$812K	Hold	83,393	–	–	0.01%	1226
2018 Q1	$725K	Hold	83,393	–	–	0.01%	1252
2017 Q4	$1.05M	Buy	+83,393	New	+$956K	0.01%	1086

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HighTower Advisors's ZYNE Position: Q3 2022 in Review

HighTower Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2022, closing a stake of 16,650 shares — an estimated $20K sold.

HighTower Advisors first reported a position in ZYNE in Q4 2017 and held it in 13 quarters. The position peaked at $1.05M in Q4 2017. 62 funds tracked by Wall St. Rank hold ZYNE as of Q3 2022.

HighTower Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
HighTower Advisors sold 16,650 Zynerba Pharmaceuticals, Inc shares in Q3 2022, an estimated $20K.
HighTower Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 13 quarters.
HighTower Advisors's Zynerba Pharmaceuticals, Inc position peaked at $1.05M in Q4 2017.
62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2022.

Based on HighTower Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.